Who are Rhgalns's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BMN 165, Elaprase, Aryplase, Aldurazyme.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/elosulfase-alfa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rhgalns — Competitive Intelligence Brief

Rhgalns (ELOSULFASE ALFA) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]. Area: Metabolic.

marketed Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC] N-acetylgalactosamine-6-sulfatase Metabolic Enzyme Live · refreshed every 30 min

Target snapshot

Rhgalns (ELOSULFASE ALFA) — BioMarin. VIMIZIM provides exogenous N-acetylgalactosamine-6-sulfatase to increase the catabolism of GAGs KS and C6S in lysosomes.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rhgalns TARGET	ELOSULFASE ALFA	BioMarin	marketed	Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]	N-acetylgalactosamine-6-sulfatase	2014-01-01
BMN 165	BMN 165	BioMarin Pharmaceutical	phase 3	Gene therapy (AAV-based)	GALNS gene (N-acetylgalactosamine-6-sulfatase)
Elaprase	IDURSULFASE	Takeda	marketed	Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]		2006-01-01
Aryplase	GALSULFASE	BioMarin	marketed	Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]		2005-01-01
Aldurazyme	LARONIDASE	BioMarin	marketed	Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]		2003-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC] class)

BioMarin · 3 drugs in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rhgalns — Competitive Intelligence Brief. https://druglandscape.com/ci/elosulfase-alfa. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab